Invesco Ltd. Grows Holdings in Moderna, Inc. (NASDAQ:MRNA)

Invesco Ltd. raised its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 17.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,883,624 shares of the company's stock after buying an additional 877,162 shares during the period. Invesco Ltd. owned about 1.52% of Moderna worth $166,801,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in shares of Moderna during the fourth quarter worth about $8,493,000. Townsquare Capital LLC increased its stake in shares of Moderna by 14.2% during the fourth quarter. Townsquare Capital LLC now owns 6,040 shares of the company's stock worth $251,000 after purchasing an additional 752 shares in the last quarter. Canada Post Corp Registered Pension Plan purchased a new stake in shares of Moderna during the fourth quarter worth about $194,000. United Capital Financial Advisors LLC increased its stake in shares of Moderna by 48.8% during the fourth quarter. United Capital Financial Advisors LLC now owns 9,059 shares of the company's stock worth $377,000 after purchasing an additional 2,972 shares in the last quarter. Finally, Altshuler Shaham Ltd increased its stake in shares of Moderna by 184.8% during the fourth quarter. Altshuler Shaham Ltd now owns 18,800 shares of the company's stock worth $782,000 after purchasing an additional 12,200 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on MRNA shares. JPMorgan Chase & Co. set a $26.00 target price on shares of Moderna in a research note on Friday, August 1st. Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. Cowen initiated coverage on shares of Moderna in a research report on Sunday, July 13th. They set a "hold" rating on the stock. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Finally, UBS Group lowered their price target on shares of Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $43.59.

Moderna Stock Performance

Moderna stock opened at $26.69 on Friday. The company's 50 day simple moving average is $29.19 and its 200-day simple moving average is $29.62. The company has a market capitalization of $10.38 billion, a price-to-earnings ratio of -3.54 and a beta of 1.83. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $91.99.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. The business had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business's revenue was down 41.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($3.33) EPS. Equities analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.